We hypothesized that isoflavone tablets would spare BMD, with biological (age, body weight, serum 25-hydroxyvitamin D) and lifestyle (physical activity, dietary intake) factors modulating BMD loss.

Design: Our double-blind, randomized controlled trial (36 mo) included healthy postmenopausal women (aged 45.8-65.0 y) with intent-to-treat (n = 224) and compliant (n = 208) analyses. Treatment groups consisted of a placebo control group and 2 soy isoflavone groups (80 compared with 120 mg/d); women received 500 mg calcium and 600 IU vitamin D3. Outcomes included

lumbar spine, total proximal femur, Nepicastat datasheet femoral neck, and whole-body BMD.

Results: Analysis of variance for intent-to-treat and compliant (>= 80%) models, respectively, showed no treatment effect for spine (P = 0.46, P = 0.21), femur (P = 0.86, P = 0.46), neck (P = 0.17, P = 0.14), or whole-body (P = 0.86, P = 0.78) BMD. From baseline to 36 mo, BMD declined regardless of treatment. In intent-to-treat and compliant models, respectively, BMD decreases were as follows: spine (-2.08%, -1.99%), femur (-1.43%, -1.38%), neck (-2.56%, -2.51%), and whole body (-1.66%, -1.62%). Regression analysis (compliant model) indicated that age, whole-body fat mass, and bone resorption were common predictors of BMD

change. After adjustment for these factors, 120 mg (compared with placebo) was protective (P = 0.024) for neck BMD. We observed no treatment effect on adverse events, endometrial thickness, or bone markers.

Conclusion: Our results do not show a bone-sparing check details effect of extracted soy isoflavones, except for a modest effect at the femoral neck. This trial was registered at clinicaltrials.gov as NCT00043745. Am J Clin Nutr 2010;91:218-30.”
“Carrier

dynamics of self-assembled InAs quantum dots (QDs) have been investigated by introducing a thin In0.32Ga0.68As layer between InAs QD layer and InAlGaAs layer, which was lattice-matched to an InP substrates. With increasing thickness of In0.32Ga0.68As layer the AG-014699 mouse photoluminescence (PL) emission of the InAs QDs is red-shifted and the PL decay time increases due to increase in QD size and improved QD shape and density. It is found that increases in QD size and/or density lead to a corresponding increase in the PL decay time. (C) 2010 American Institute of Physics. [doi:10.1063/1.3506709]“
“Triple-negative breast cancer (TNBC) is characterized by lack of hormone receptors and HER-2 and shares many features with BRCA1-associated cancer. Preclinical data indicate cisplatin sensitivity, suggesting that these tumors may have defects in the BRCA1 pathway. The carboplatin and gemcitabine (CG) combination is active in unselected anthracycline/taxane pretreated metastatic breast cancer patients, so we carried out a phase II study to evaluate the activity of the CG combination in pretreated metastatic TNBC patients.